Drug Trial Radar · NCT07342478
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
306
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Oct 30, 2029
Study completion Jul 30, 2030
Sponsor
- Lead sponsor
- Newave Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no), reason for discontinuation of prior cBTKi therapy (toxicity vs disease progression), prior exposure to a BCL2 inhibitor (yes/no), and region (United States/China/rest of world). The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC) using iwCLL 2018 criteria for CLL and Lugano 2014 criteria for SLL. Key secondary objectives include overall survival, overall response rate, time-to-event outcomes, and safety/tolerability; exploratory objectives include health-related quality of life and biomarker assessments.
Conditions
- CLL / SLL
- CLL (Chronic Lymphocytic Leukemia)
- CLL, Refractory
- CLL, Relapsed
- SLL (Small Lymphocytic Lymphoma)
- SLL
- CLL
- CLL Progression
Interventions
RocbrutinibDrug
The new generation, highly potent, ultra-selective BTK inhibitor with covalent and non-covalent dual binding mechanism, targeting both WT BTK and mutant BTK
PirtobrutinibDrug
Pirtobrutinib is a non-covalent BTK inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS assessed by IRCTime frame: From randomization until disease progression or death from any cause, assessed up to approximately 4 years.
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Orchard Healthcare Research
Skokie, Illinois · Recruiting
The Center for Cancer and Blood Disorders-Bethesda
Bethesda, Maryland · Recruiting
Optum Medical Group (Rhodes) P.C.
Las Vegas, Nevada · Recruiting
Duke Adult Blood and Marrow Clinic
Durham, North Carolina · Recruiting
OSU Comprehensive Cancer Center
Columbus, Ohio · Not yet recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Medical Oncology Associates - Spokane
Spokane, Washington · Recruiting
Institut Bergonié
Bordeaux, France · Recruiting
Centre Hospitalier Le Mans
Le Mans, France · Recruiting
CHRU Tours Bretonneau
Tours, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.